Martin J. Driscoll Buys 2,000 Shares of Spring Bank Pharmaceuticals Inc (SBPH) Stock
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) insider Martin J. Driscoll acquired 2,000 shares of Spring Bank Pharmaceuticals stock in a transaction dated Wednesday, November 9th. The stock was purchased at an average price of $8.84 per share, with a total value of $17,680.00. Following the completion of the purchase, the insider now directly owns 24,500 shares of the company’s stock, valued at approximately $216,580. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) opened at 8.1636 on Monday. The firm’s market capitalization is $63.41 million. Spring Bank Pharmaceuticals Inc has a 52 week low of $7.47 and a 52 week high of $13.25. The stock has a 50 day moving average of $10.76 and a 200-day moving average of $10.67.
SBPH has been the subject of a number of analyst reports. William Blair initiated coverage on shares of Spring Bank Pharmaceuticals in a research note on Friday, August 19th. They issued an “outperform” rating and a $26.00 price objective for the company. Dawson James restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Sunday, November 6th.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of therapeutics using its small molecule nucleic acid hybrid (SMNH), chemistry platform. Its SMNH compounds are small segments of nucleic acids that the Company designs to selectively target and modulate the activity of specific proteins implicated in various disease states.
Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.